How to buy Inhibrx stock | $34.23

Inhibrx, Inc is a biotechnology business based in the US. Inhibrx shares (INBX) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibrx employs 75 staff and has a trailing 12-month revenue of around USD$10.4 million.

How to buy shares in Inhibrx

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Inhibrx. Find the stock by name or ticker symbol: INBX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Inhibrx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$34.23, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Inhibrx, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Inhibrx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Inhibrx share price

Use our graph to track the performance of INBX stocks over time.

Inhibrx shares at a glance

• Key figures

Information last updated 2020-12-07.

Latest market close	USD$34.23
52-week range	USD$15.2 - USD$36.97
50-day moving average	USD$22.2465
200-day moving average	USD$19.9282
Wall St. target price	USD$30.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Inhibrx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Inhibrx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Inhibrx, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inhibrx price performance over time

Historical closes compared with the close of $34.23 from 2020-12-09

1 week (2021-01-07)	-0.84%
1 month (2020-12-17)	-31.54%
3 months (2020-10-16)	95.15%
6 months (2020-07-13)	N/A

1 year (2020-01-13)	N/A
2 years (2019-01-13)	N/A
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

Inhibrx financials

Revenue TTM	USD$10.4 million
Gross profit TTM	USD$-34,696,000
Return on assets TTM	-47.07%
Return on equity TTM	-259.35%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$1.4 billion

TTM: trailing 12 months

Shorting Inhibrx shares

There are currently 265,399 Inhibrx shares held short by investors – that's known as Inhibrx's "short interest". This figure is 22.1% up from 217,327 last month.

There are a few different ways that this level of interest in shorting Inhibrx shares can be evaluated.

Inhibrx's "short interest ratio" (SIR)

Inhibrx's "short interest ratio" (SIR) is the quantity of Inhibrx shares currently shorted divided by the average quantity of Inhibrx shares traded daily (recently around 57947.379912664). Inhibrx's SIR currently stands at 4.58. In other words for every 100,000 Inhibrx shares traded daily on the market, roughly 4580 shares are currently held short.

However Inhibrx's short interest can also be evaluated against the total number of Inhibrx shares, or, against the total number of tradable Inhibrx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inhibrx's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inhibrx shares in existence, roughly 10 shares are currently held short) or 0.0113% of the tradable shares (for every 100,000 tradable Inhibrx shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inhibrx.

Find out more about how you can short Inhibrx stock.

Inhibrx share dividends

We're not expecting Inhibrx to pay a dividend over the next 12 months.

Inhibrx overview

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.

Frequently asked questions

• What percentage of Inhibrx is owned by insiders or institutions?

  Currently 34.346% of Inhibrx shares are held by insiders and 36.655% by institutions.

• How many people work for Inhibrx?

  Latest data suggests 75 work at Inhibrx.

• When does the fiscal year end for Inhibrx?

  Inhibrx's fiscal year ends in December.

• Where is Inhibrx based?

  Inhibrx's address is: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037

• What is Inhibrx's ISIN number?

  Inhibrx's international securities identification number is: US45720L1070